Warm Congratulations Focusfreda Successfully Completes Technical Review of Sodium Hyaluronate API Officially Upgraded to Category A Filing Status
On April 7, the National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) officially announced that Focusfreda's self-developed sodium hyaluronate active pharmaceutical ingredient (API) (Registration No.: Y20230000698) has passed the technical review and been upgraded to Category A filing status. This product marks Focusfreda's first API to achieve Category A filing in the pharmaceutical field, signifying a major breakthrough in the company's drug R&D and registration capabilities. Recently, the company has achieved frequent milestones in the pharmaceutical raw material sector, steadily advancing its strategic transformation and upgrading toward high-end pharmaceutical industries.
As a key active ingredient in ophthalmic preparations, sodium hyaluronate API is primarily used in the production of sodium hyaluronate eye drops, demonstrating significant clinical value in alleviating ophthalmic diseases such as dry eye syndrome. Obtaining the Category A filing not only highlights Focusfreda's professional expertise and technological prowess in pharmaceutical R&D but also underscores the company's forward-looking strategic positioning in the ophthalmic drug market and its comprehensive advantages in end-to-end management spanning R&D, production, and quality control. Looking ahead, Focusfreda will continue to deepen its focus on pharmaceutical innovation, optimizing production processes, enhancing quality standards, and increasing R&D investments to build a globally competitive platform for medical innovation. The company remains committed to delivering safer, higher-quality pharmaceutical products and service solutions to patients worldwide.
RECOMMENDED READING
CONTACT US
Tel：+86-0537-3195566
E-mail：sales@focuschem.com
Add：Economic Development Zone, High-speed Railway New District, Qufu City, Jining City, Shandong Province, China
Copyright © 2022 Shandong Focusfreda Biotech Co., Ltd. 鲁ICP备2021008509号-2 Powerby : 300.cn jinan SEO